JPH0154326B2 - - Google Patents
Info
- Publication number
- JPH0154326B2 JPH0154326B2 JP56128291A JP12829181A JPH0154326B2 JP H0154326 B2 JPH0154326 B2 JP H0154326B2 JP 56128291 A JP56128291 A JP 56128291A JP 12829181 A JP12829181 A JP 12829181A JP H0154326 B2 JPH0154326 B2 JP H0154326B2
- Authority
- JP
- Japan
- Prior art keywords
- fluoromethylhistidine
- cimetidine
- methyl
- nim
- trityl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- AJFGLTPLWPTALJ-SSDOTTSWSA-N (2s)-2-azaniumyl-2-(fluoromethyl)-3-(1h-imidazol-5-yl)propanoate Chemical compound FC[C@@](N)(C(O)=O)CC1=CN=CN1 AJFGLTPLWPTALJ-SSDOTTSWSA-N 0.000 claims description 31
- 229960001380 cimetidine Drugs 0.000 claims description 22
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 claims description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 208000007107 Stomach Ulcer Diseases 0.000 claims description 7
- 230000027119 gastric acid secretion Effects 0.000 claims description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 20
- 208000027418 Wounds and injury Diseases 0.000 description 18
- 230000006378 damage Effects 0.000 description 18
- 208000014674 injury Diseases 0.000 description 18
- -1 (+)-Methyl α-fluoromethylhistidine 1,5-naphthalenedisulfonate Chemical compound 0.000 description 15
- 239000000203 mixture Substances 0.000 description 15
- 150000003839 salts Chemical class 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 229940079593 drug Drugs 0.000 description 13
- 239000003814 drug Substances 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 239000013078 crystal Substances 0.000 description 11
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 10
- 238000003756 stirring Methods 0.000 description 9
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 230000037396 body weight Effects 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 229960001340 histamine Drugs 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 4
- LIJUCORJKQZTOS-XCUBXKJBSA-N (2s)-2-amino-2-(fluoromethyl)-3-(1h-imidazol-5-yl)propanoic acid;dihydrochloride Chemical compound Cl.Cl.FC[C@@](N)(C(O)=O)CC1=CN=CN1 LIJUCORJKQZTOS-XCUBXKJBSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 239000011885 synergistic combination Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- NJQADTYRAYFBJN-FWWHASMVSA-N (1s,2s,4r)-2-bromo-4,7,7-trimethylbicyclo[2.2.1]heptan-3-one Chemical compound C1C[C@@]2(C)C(=O)[C@@H](Br)[C@@H]1C2(C)C NJQADTYRAYFBJN-FWWHASMVSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229940084460 cimetidine 100 mg Drugs 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 210000004211 gastric acid Anatomy 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- XTEGVFVZDVNBPF-UHFFFAOYSA-L naphthalene-1,5-disulfonate(2-) Chemical compound C1=CC=C2C(S(=O)(=O)[O-])=CC=CC2=C1S([O-])(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-L 0.000 description 2
- XTEGVFVZDVNBPF-UHFFFAOYSA-N naphthalene-1,5-disulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1S(O)(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- AJTAPCUFVRUIEO-OGFXRTJISA-N (2s)-2-amino-2-(fluoromethyl)-3-(1h-imidazol-5-yl)propanoic acid;hydrochloride Chemical compound Cl.FC[C@@](N)(C(O)=O)CC1=CN=CN1 AJTAPCUFVRUIEO-OGFXRTJISA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- FSSICIQKZGUEAE-UHFFFAOYSA-N 2-[benzyl(pyridin-2-yl)amino]ethyl-dimethylazanium;chloride Chemical compound Cl.C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CC=C1 FSSICIQKZGUEAE-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 208000012895 Gastric disease Diseases 0.000 description 1
- 102000003834 Histamine H1 Receptors Human genes 0.000 description 1
- 108090000110 Histamine H1 Receptors Proteins 0.000 description 1
- 102000003710 Histamine H2 Receptors Human genes 0.000 description 1
- 108090000050 Histamine H2 Receptors Proteins 0.000 description 1
- 102000000543 Histamine Receptors Human genes 0.000 description 1
- 108010002059 Histamine Receptors Proteins 0.000 description 1
- 101150056637 Hrh2 gene Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229960004977 anhydrous lactose Drugs 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 1
- 229960003291 chlorphenamine Drugs 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 229960001677 cyclizine hydrochloride Drugs 0.000 description 1
- UKPBEPCQTDRZSE-UHFFFAOYSA-N cyclizine hydrochloride Chemical compound Cl.C1CN(C)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 UKPBEPCQTDRZSE-UHFFFAOYSA-N 0.000 description 1
- JJCFRYNCJDLXIK-UHFFFAOYSA-N cyproheptadine Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 JJCFRYNCJDLXIK-UHFFFAOYSA-N 0.000 description 1
- 229960001140 cyproheptadine Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000006642 detritylation reaction Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- MZDOIJOUFRQXHC-UHFFFAOYSA-N dimenhydrinate Chemical compound O=C1N(C)C(=O)N(C)C2=NC(Cl)=N[C]21.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 MZDOIJOUFRQXHC-UHFFFAOYSA-N 0.000 description 1
- 229960004993 dimenhydrinate Drugs 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000138 effect on histamine Effects 0.000 description 1
- LBAQSKZHMLAFHH-UHFFFAOYSA-N ethoxyethane;hydron;chloride Chemical compound Cl.CCOCC LBAQSKZHMLAFHH-UHFFFAOYSA-N 0.000 description 1
- MHYCRLGKOZWVEF-UHFFFAOYSA-N ethyl acetate;hydrate Chemical compound O.CCOC(C)=O MHYCRLGKOZWVEF-UHFFFAOYSA-N 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940077716 histamine h2 receptor antagonists for peptic ulcer and gord Drugs 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229940041476 lactose 100 mg Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical compound C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 229960000620 ranitidine Drugs 0.000 description 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- XHFLOLLMZOTPSM-UHFFFAOYSA-M sodium;hydrogen carbonate;hydrate Chemical compound [OH-].[Na+].OC(O)=O XHFLOLLMZOTPSM-UHFFFAOYSA-M 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- UJJLJRQIPMGXEZ-UHFFFAOYSA-N tetrahydro-2-furoic acid Chemical compound OC(=O)C1CCCO1 UJJLJRQIPMGXEZ-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17935880A | 1980-08-18 | 1980-08-18 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5759812A JPS5759812A (en) | 1982-04-10 |
| JPH0154326B2 true JPH0154326B2 (es) | 1989-11-17 |
Family
ID=22656255
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP56128291A Granted JPS5759812A (en) | 1980-08-18 | 1981-08-18 | Synergistic blend of (r,s)alpha- fluoromethylhistidine and cimetidine as antiulcer |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP0046290B1 (es) |
| JP (1) | JPS5759812A (es) |
| AU (1) | AU7398381A (es) |
| DD (1) | DD200404A5 (es) |
| DE (1) | DE3168036D1 (es) |
| FI (1) | FI812469L (es) |
| GR (1) | GR74627B (es) |
| PT (1) | PT73517B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4447443A (en) * | 1982-11-15 | 1984-05-08 | Merck & Co., Inc. | Anti-inflammatory/analgesic combination of α-fluoromethylhistidine and a selected non-steroidal anti-inflammatory drug (NSAID) |
| US5030645A (en) * | 1990-10-15 | 1991-07-09 | Merck & Co., Inc. | Method of treating asthma using (S)-α-fluoromethyl-histidine and esters thereof |
| FR2822709B1 (fr) * | 2001-03-30 | 2007-01-19 | Antialis | Composition pharmaceutique anti-allergique comprenant au moins un allergene et au moins un compose antihistaminique |
| FR2896156A1 (fr) * | 2006-01-17 | 2007-07-20 | Gaetan Terrasse | Nouvelle utilisation de la tritoqualine en association avec des substances medicamenteuses antagonistes du recepteur h2 a l'histamine,pour le traitement des maladies inflammatoires digestives |
| EP2170317A4 (en) * | 2007-02-12 | 2011-03-23 | Mike Nicolaou | TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), GASTRO-OESOPHAGEAL REFLUX DISEASE (GERD), FOOD ALLERGIES, AND OTHER DISEASES AND GASTROINTESTIN DISORDERS AFFECTED BY APPROPRIATE MANAGEMENT OF HISTAMINE USING A COMBINATION OF INHIBITORS HISTIDINE DECARBOXYLASE, MEDICAMEN |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4000302A (en) * | 1972-04-20 | 1976-12-28 | Smith Kline & French Laboratories Limited | Pharmaceutical compositions and methods of inhibiting H-1 and H-2 histamine receptors |
| US4215221A (en) * | 1977-06-01 | 1980-07-29 | Merck & Co., Inc. | Fluorination process |
-
1981
- 1981-08-10 FI FI812469A patent/FI812469L/fi not_active Application Discontinuation
- 1981-08-11 AU AU73983/81A patent/AU7398381A/en not_active Abandoned
- 1981-08-13 DD DD81232586A patent/DD200404A5/de unknown
- 1981-08-13 PT PT73517A patent/PT73517B/pt unknown
- 1981-08-14 GR GR65799A patent/GR74627B/el unknown
- 1981-08-17 EP EP81106371A patent/EP0046290B1/en not_active Expired
- 1981-08-17 DE DE8181106371T patent/DE3168036D1/de not_active Expired
- 1981-08-18 JP JP56128291A patent/JPS5759812A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| AU7398381A (en) | 1982-02-25 |
| PT73517A (en) | 1981-09-01 |
| EP0046290B1 (en) | 1985-01-02 |
| PT73517B (en) | 1983-07-06 |
| DD200404A5 (de) | 1983-05-04 |
| EP0046290A1 (en) | 1982-02-24 |
| JPS5759812A (en) | 1982-04-10 |
| FI812469L (fi) | 1982-02-19 |
| GR74627B (es) | 1984-06-29 |
| DE3168036D1 (en) | 1985-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Clarke et al. | Compounds affecting the central nervous system. 4. 3. beta.-phenyltropane-2-carboxylic esters and analogs | |
| EA022530B1 (ru) | Бис-(фторалкил)-1,4-бензодиазепиноновые соединения | |
| AU2004255191A1 (en) | Phenylcarboxylate beta-secretase inhibitors for the treatment of Alzheimer's disease | |
| US4299838A (en) | Tryptophan derivatives having an increased effect on the central nervous system | |
| JPS6049192B2 (ja) | 新規置換ベンズアミド、その製造方法及びこれを有効成分とする向精神薬 | |
| KR100191989B1 (ko) | 신규한 결정형의 무수7-((1알파,5알파,6알파)-6-아미노-3-아자비사이클로(3.1.0)헥스-3-일)-6-플루오로-1-(2,4-디플루오로페닐)-1,4-디하이드로-4-옥소-1,8-나프티리딘-3-카복실산 메탄설폰산 염 | |
| GB2243832A (en) | 2-substituted 4-acetamido-5-chloro-n-[2-(diethylamino)ethyl]-benzamide derivative | |
| EP0047536A2 (en) | Substituted propylamines | |
| US4528289A (en) | Corynantheine derivates, processes for their preparation, and their use | |
| JPH0154326B2 (es) | ||
| US4304785A (en) | Dilignols and dilignol-type compounds | |
| HU211269A9 (en) | Piperazinecarboxylic acid its preparation and pharmaceutical compositions containing it | |
| PL80112B1 (es) | ||
| US4435420A (en) | Anti-inflammatory agents and antiasthmatic agents | |
| US4512994A (en) | Long-acting theophylline in medicinal form | |
| HU194877B (en) | Process for producing morpholinoethyl-ester-diniflumate of nifluminic acid and pharmaceutical composition containing them | |
| SK152095A3 (en) | Crystalline (+) l-hydrogentartrate, preparation method thereof, pharmaceutical composition containing its and its use | |
| US5990104A (en) | Polycyclic alcaloid-derivatives as NMDA-receptor antagonists | |
| US6201011B1 (en) | Therapeutic agent for allergic dermatitis | |
| JPH0615553B2 (ja) | ジヒドロピリジン−５−ホスホンアミド酸類 | |
| US4614743A (en) | Methods of treating pain and inflammation with 4,7-dimethyl-2-(4-pyridinyl)-1,2,4,-triazolo[1,5-a]pyrimidin-5(4H)-one or the pharmaceutically acceptable salts or solvates thereof | |
| US5508401A (en) | Substituted dibenzo[a,d]cycloheptene NMDA antagonists | |
| RU2173146C2 (ru) | Производные полициклических алкалоидов как антагонисты nmda-рецептора | |
| KR100188575B1 (ko) | 벤즈이미다졸 유도체, 그의 제조법, 그를 유효성분으로서 함유하는 제토제 및 그의 제조용 중간체 | |
| JPS6354687B2 (es) |